Articles

Researchers evaluating the Bruton’s tyrosine kinase inhibitor acalabrutinib monotherapy in relapsed/refractory and high-risk, treatment-naïve chronic lymphocytic leukemia (CLL) patients reported high response rates and an acceptable safety profile. Read More ›

Using a national claims database, researchers found that previously untreated patients receiving chemoimmunotherapy had a higher total cost of care compared with patients receiving single-agent ibrutinib. Read More ›

This phase 3 follow-up analysis evaluates the efficacy and safety of ibrutinib, alone and in combination with rituximab, in patients with Waldenström’s macroglobulinemia. Read More ›

In an ex vivo analysis, the combination of venetoclax and ibrutinib showed encouraging biologic activity in several leukemia subtypes, including acute myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Read More ›

In a phase 2 trial, the combination of ibrutinib and venetoclax was effective in patients with previously untreated, high-risk chronic lymphocytic leukemia (CLL), with no unforeseen safety signals. Read More ›

Researchers evaluated venetoclax plus rituximab versus bendamustine plus rituximab in inducing deep, durable responses in patients with chronic lymphocytic leukemia, as measured by the rate of minimal residual disease. Read More ›

The combination of ibrutinib with obinutuzumab represents an effective chemotherapy-free treatment option for first-line chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), including patients with high-risk genetic abnormalities. Read More ›

The Bruton’s tyrosine kinase inhibitor acalabrutinib shows promise as a tolerable, effective monotherapy option for patients with previously untreated chronic lymphocytic leukemia. Read More ›

In evaluating the combination regimen of obinutuzumab, ibrutinib, and venetoclax as a potential limited-duration option in chronic lymphocytic leukemia (CLL), researchers reported a high mid-therapy response rate of relapsed/refractory patients with promising rates of minimal residual disease–negativity. Read More ›

The ALLIANCE study showed that ibrutinib produces superior progression-free survival to standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL). Read More ›